and Human Services (HHS)
EXPIRED
Department
of Health and Human Services
Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov)
Components of Participating Organizations
All NIH Institutes and Centers participate in
this NIH-wide announcement. This FOA is being administered by the
National Institute of General Medical Sciences (NIGMS) on behalf of NIH.
Title: Recovery Act Limited Competition: The NIH
Director’s ARRA Funded Pathfinder Award to Promote Diversity in the Scientific
Workforce (DP4)
Announcement
Type
This is a new FOA.
Update: The following update relating to this announcement has been issued:
Request for Applications (RFA) Number: RFA-OD-10-013
NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.
APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.
This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants (hereafter called Grants.gov/Apply).
A registration process is necessary before submission and applicants are highly encouraged to start the process at least four (4) weeks prior to the grant submission date. See Section IV.
Catalog
of Federal Domestic Assistance Number(s)
93.701
Key Dates
Release/Posted Date: March 5, 2010
Opening Date: April 4, 2010 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): April 5, 2010
NOTE: On-time submission requires that applications be successfully
submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant
institution/organization).
Application Due
Date(s): May 4, 2010
Peer Review Date(s): July 2010
Council Review Date(s): August 2010
Earliest Anticipated Start Date(s): August 31, 2010
Additional Information to Be Available Date
(Activation Date): Frequently
Asked Questions (FAQs) at http://grants.nih.gov/recovery/faqs_directors_pathfinder.html
Expiration
Date: May 5, 2010
Additional
Overview Content
Executive Summary
Table of Contents
Part I Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity Description
Section II. Award Information
Section
III. Eligibility Information
Section
IV. Application and Submission Information
Section
V. Application Review Information
Section
VI. Award Administration Information
Section
VII. Agency Contacts
Section
VIII. Other Information - Required Federal Citations
Part II - Full Text of Announcement
Section I. Funding Opportunity Description
Research
Objectives
Concerns
about diversity are based on reports from the National Science Foundation
(NSF), (see http://www.nsf.gov/statistics/wmpd/) and other
sources that provide evidence that lack of diversity remains an important
problem for the biomedical research workforce. In addition, there is a
growing body of evidence that the research enterprise will directly benefit
from broader inclusion. Recent studies indicate that diversity enhances the
quality of education in multiple settings. Studies have suggested that racially
and culturally concordant scientific staff may be more successful in recruiting
individuals from minority groups into clinical trials. Racially similar
physician-patient dyads also appear to be related to greater patient
satisfaction in ways that could enhance communication and participation in
clinical research settings.
The NIH Director’s ARRA Pathfinder Award to Promote Diversity in the Scientific Workforce is designed to foster new ways of thinking about research related to scientific workforce diversity. It is expected to fill fundamental knowledge gaps and to encourage the development of new approaches to this complex problem that has eluded solution for decades. The Director’s Pathfinder Award is designed to support extremely creative individual scientists who propose innovative and possibly transforming approaches to this major challenge to biomedical research. The proposed approaches should have the potential to produce an unusually high impact in an area of research on workforce diversity. The proposed research must reflect ideas substantially different from those already being pursued in the investigator’s laboratory or at the investigator’s institution or elsewhere. The proposal should describe new interventions that have the capacity to improve workforce diversity in new ways incorporating strong research designs to assess unambiguously the effects of those interventions.
Biomedical research is defined broadly in this announcement as encompassing scientific investigations in the biological, behavioral, clinical, social, physical, chemical, computational, engineering, and mathematical sciences that have the potential to improve public health. The scientific workforce includes all individuals who work in biomedical research including undergraduate and graduate students, postdoctorates, and faculty. Interventions designed to improve diversity can include these populations as well as populations that feed into these levels. For the Director’s Pathfinder program, diversity can address the participation of individuals currently underrepresented in the biomedical, clinical, behavioral, and social sciences on a national basis including: individuals from underrepresented racial and ethnic groups; individuals with disabilities; individuals from socially, culturally, economically, or educationally disadvantaged backgrounds that have inhibited their ability to pursue a career in health-related research; and women at the faculty level. The research conducted with support by Director’s Pathfinder Award can address diversity on a national or institutional basis.
The Director’s Pathfinder initiative is designed to support investigators who intend to pursue new research directions related to workforce diversity research that is distinct from that currently or previously conducted by the investigator. Applications for projects that are extensions of ongoing research should not be submitted. Director’s Pathfinder awardees are required to commit a major portion (generally 30% or more) of their research effort to activities supported by the Director’s Pathfinder Award. Those who cannot approach an effort requirement at or near this level should not submit applications. Those with effort levels less than 30% must provide evidence that the effort committed will be sufficient to carry out the proposed research. All applications must be submitted as new applications regardless of any previous submission. The proposed research must be endorsed by the highest levels of institutional management.
See Section VIII, Other
Information - Required Federal Citations, for laws and policies related to this
announcement.
Section II. Award Information
1. Mechanism of Support
This FOA will use the DP4 award mechanism. The Project Director/Principal Investigator
(PD/PI) will be solely responsible for planning,
directing, and executing the proposed project.
This FOA uses Just-in-Time information concepts (see SF424 (R&R) Application Guide).
2. Funds
Available
This
initiative is supported
by funds provided to the NIH under the American Recovery &
Reinvestment Act of 2009 ( Recovery Act or ARRA ), Public Law 111-5. NIH has designated approximately $10 M
to provide up to 5 awards, contingent upon the submission of a sufficient
number of meritorious applications.
Budget proposals are limited to $2,000,000 in total costs over a three year project period. Facilities and Administrative (F&A) costs are included within this total award amount.
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size of each award will also vary. Although the financial plans of the NIH provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds.
This program is supported by funds provided to the NIH under the Recovery Act. The purpose of the Recovery Act is to stimulate the American economy through job preservation and creation, infrastructure investment, energy efficiency and science, and other means. Consistent with these goals, domestic (United States) institutions/organizations planning to submit applications that include foreign components should be aware that requested funding for any foreign component should not exceed 10% of the total requested direct costs or $25,000 per year (aggregate total for a subcontract or multiple subcontracts), whichever is less.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Section III. Eligibility Information
1.
Eligible Applicants
1.A.
Eligible Institutions
The
following organizations/institutions are eligible to apply. Consistent with the purposes of the Recovery Act (in particular,
to preserve and create jobs and promote economic recovery in the United
States, and to provide investments needed to increase economic efficiency by
spurring technological advances in science and health), applicants must be a
domestic (United States) institution/organization. The United States institution/organization must be located in the 50 states, territories and possessions
of the U.S., Commonwealth of Puerto Rico, Trust Territory of the Pacific
Islands, or District of Columbia. NIH encourages
applications from all interested organizations/institutions, including those
from Institutional
Development Award (IDeA) states and Academic
Research Enhancement Award (AREA)-eligible institutions. Foreign organizations/institutions are not permitted as the applicant organization.
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
2. Cost
Sharing or Matching
This program does not require cost sharing as
defined in the current NIH Grants Policy Statement.
3. Other-Special Eligibility Criteria
Number of Applications. Applicants may submit only one application as a PD/PI in response to this FOA. There is no limit to the number of applications that an institution may submit.
Number of PDs/PIs. Only one PD/PI (i.e., no multiple PDs/PIs) may be designated on the application.
Resubmissions. Resubmission applications are not permitted in response to this FOA.
Renewals. Renewal applications are not permitted in response to this FOA. All applications will be considered new applications.
Section IV. Application and Submission Information
To download a SF424
(R&R) Application Package and SF424 (R&R) Application Guide for
completing the SF424 (R&R) forms for this FOA, use the Apply for Grant
Electronically button in this FOA or link to http://www.grants.gov/Apply/ and follow the directions provided on that
Web site.
Registration:
Appropriate registrations with Grants.gov and eRA Commons must be completed on or before the due date in order to successfully submit an application. Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered with both Grants.gov and the Commons. All registrations must be complete by the submission deadline for the application to be considered on-time (see 3.C.1 for more information about on-time submission).
A one-time registration is required for institutions/organizations at both:
PDs/PIs should work with their institutions/organizations to make sure they are registered in the NIH eRA Commons.
Several additional separate actions are required before an applicant can submit an electronic application, as follows:
1) Organizational/Institutional Registration in Grants.gov/Get Registered
2) Organizational/Institutional Registration in the eRA Commons
3) Project Director/Principal Investigator (PD/PI) Registration in the NIH eRA Commons: Refer to the NIH eRA Commons System (COM) Users Guide.
Both the PD/PI and AOR/SO need separate accounts in the NIH eRA Commons since both are authorized to view the application image.
Note: The registration process is not sequential. Applicants should begin the registration processes for both Grants.gov and eRA Commons as soon as their organization has obtained a DUNS number. Only one DUNS number is required and the same DUNS number must be referenced when completing Grants.gov registration, eRA Commons registration and the SF424 (R&R) forms.
Note that for this FOA, only one PID/PI will be allowed (i.e., no multiple PD/PIs.)
1. Request Application Information
Applicants must download the SF424 (R&R)
application forms and the SF424 (R&R) Application Guide for this FOA
through Grants.gov/Apply.
Note: Only
the forms package directly attached to a specific FOA can be used. You will not
be able to use any other SF424 (R &R) forms (e.g., sample forms, forms from
another FOA); although some of the "Attachment" files may be useable
for more than one FOA.
For further assistance, contact GrantsInfo --
Telephone 301-710-0267; Email: [email protected].
Telecommunications for the hearing impaired: TTY: (301) 451-5936
2. Content and Form of Application Submission
Prepare all applications using the SF424 (R&R) application forms for this FOA through Grants.gov/Apply and in accordance with the SF424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/index.htm).
The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to NIH. Some fields within the SF424 (R&R) application components, although not marked as mandatory, are required by NIH (e.g., the Credential log-in field of the Research & Related Senior/Key Person Profile component must contain the PD/PI’s assigned eRA Commons User ID). Agency-specific instructions for such fields are clearly identified in the Application Guide. For additional information, see Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
The
exceptions from the SF424 instructions and detailed information on the
application structure and components are provided in section IV.6, Other
Submission Requirements. All applicants must follow the specific
instructions in that section.
The SF424 (R&R) application has several components. Some components are
required, others are optional. The forms package associated with this FOA in Grants.gov/APPLY includes all applicable components, required and optional. A completed
application in response to this FOA includes the data in the following
components:
Required
Components:
SF424 (R&R) (Cover component)
Research & Related Project/Performance Site Locations
Research & Related Other Project
Information
Research & Related Senior/Key Person
Research & Related Budget
PHS 398 Cover Page Supplement
PHS 398 Research Plan
PHS 398 Checklist
Optional Components:
PHS398 Cover Letter File
Research & Related Subaward Budget Attachment Form
3.
Submission Dates and Times
See Section IV.3.A. for details.
3.A. Submission,
Review, and Anticipated Start Dates
Opening Date: April 4, 2010 (Earliest date an application may be
submitted to Grants.gov)
Letters of Intent Receipt Date(s): April 5, 2010
Application Due Date(s): May 4, 2010
Peer Review Date(s): July, 2010
Council Review Date(s): August 2010
Earliest Anticipated Start Date(s): August
31, 2010
3.A.1. Letter of Intent
Although the Letter of Intent (LOI) is not required, not binding and does not enter into the review of the subsequent application, an applicant may choose to submit one. The information that the LOI contains allows IC staff to estimate and plan for the potential review workload. Prospective applicants are asked to submit a LOI that includes the following information:
The letter of intent is to be sent by the date listed in Section IV.3.A.
The letter of intent
should be sent to:
John Firrell Ph.D.
Scientific Review Officer
Surgical Sciences, Biomedical Imaging and Bioengineering IRG
Center for Scientific Review
National Institutes of Health
6701 Rockledge Dr, Room 5118
Bethesda, MD 20892
Phone: (301) 435-2598
Fax (301) 480-2241
[email protected]
3.B. Submitting an Application
Electronically to the NIH
To submit an application in response to this FOA, applicants should access this
FOA via http://www.grants.gov/applicants/apply_for_grants.jsp and follow Steps 1-4. Note:
Applications must only be submitted electronically. PAPER
APPLICATIONS WILL NOT BE ACCEPTED. All attachments must be provided to NIH in PDF format, filenames must
be included with no spaces or special characters, and a .pdf extension must be
used.
3.C. Application Processing
3.C.1
Submitting On-Time
Applications may be submitted on or after the opening date and must be successfully received by Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization) on the application due date(s). (See Section IV.3.A. for all dates.) If an application is not submitted by the due date(s) and time, the application may be delayed in the review process or not reviewed.
All applications must meet the following criteria to be considered on-time :
Please visit http://era.nih.gov/electronicReceipt/app_help.htm for detailed information on what to do if Grants.gov or eRA system issues threaten your ability to submit on time.
Submission to Grants.gov is not the last step applicants must follow their application through to the eRA Commons to check for errors and warnings and view their assembled application!
3.C.2 Two Day Window to Correct eRA Identified Errors/Warnings
IMPORTANT NOTE! NIH has eliminated the error correction window for due dates of January 25, 2011 and beyond. As of January 25, all corrections must be complete by the due date for an application to be considered on-time. See NOT-OD-10-123.
Once an application package has been successfully submitted through Grants.gov,
NIH provides applicants a two day error correction window to correct any eRA identified errors or warnings before a final assembled application is created in the eRA Commons. The standard error correction window is two (2) business days, beginning the day after the submission deadline and excluding weekends and standard federal holidays. All errors must be corrected to successfully complete the submission process. Warnings will not prevent the application from completing the submission process.
Please note that the following caveats apply:
3.C.3 Viewing an Application in the eRA Commons
Once any eRA identified errors have been addressed, and the assembled application has been created in the eRA Commons, the PD/PI and the Authorized Organization Representative/Signing Official (AOR/SO) have two weekdays (Monday Friday, excluding Federal holidays) to view the assembled application before it automatically moves forward to NIH for further processing.
Upon receipt, applications will be evaluated for completeness by the CSR and responsiveness by the IC. Incomplete and/or non-responsive applications will not be reviewed.
There will be an acknowledgement of receipt of applications from Grants.gov and the Commons. The submitting AOR/SO receives the Grants.gov acknowledgments. The AOR/SO and the PI receive Commons acknowledgments. Information related to the assignment of an application to a Scientific Review Group is also in the Commons.
Note: Since email can be unreliable, it is the responsibility of the applicant to check periodically on the application status in the Commons.
The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. However, when a previously unfunded application, originally submitted as an investigator-initiated application, is to be submitted in response to a funding opportunity, it is to be prepared as a NEW application. That is, the application for the funding opportunity must not include an Introduction describing the changes and improvements made, and the text must not be marked to indicate the changes from the previous unfunded version of the application.
4.
Intergovernmental Review
This initiative is not subject to intergovernmental review.
5. Funding
Restrictions
All NIH awards are subject to the terms and
conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award
costs are allowable. A grantee may, at its own risk and without NIH prior
approval, incur obligations and expenditures to cover costs up to 90 days
before the beginning date of the initial budget period of a new award if such
costs: 1) are necessary to conduct the project, and 2) would be allowable under
the grant, if awarded, without NIH prior approval. If specific expenditures
would otherwise require prior approval, the grantee must obtain NIH approval
before incurring the cost. NIH prior approval is required for any costs to be
incurred more than 90 days before the beginning date of the initial budget
period of a new award.
The incurrence of pre-award costs in
anticipation of a competing or non-competing award imposes no obligation on NIH
either to make the award or to increase the amount of the approved budget if an
award is made for less than the amount anticipated and is inadequate to cover
the pre-award costs incurred. NIH expects the grantee to be fully aware that
pre-award costs result in borrowing against future support and that such borrowing
must not impair the grantee's ability to accomplish the project objectives in
the approved time frame or in any way adversely affect the conduct of the
project (see the NIH Grants Policy Statement).
None of the funds appropriated or otherwise made available in ARRA may be used by any state or local government, or any private entity, for any casino or other gambling establishment, aquarium, zoo, golf course, or swimming pool. (ARRA Sec. 1604)
6. Other Submission Requirements
PD/PI Credential (e.g., Agency Login)
The NIH requires the PD(s)/PI(s) to fill in his/her Commons User ID in the PROFILE Project Director/Principal Investigator section, Credential log-in field of the Research & Related Senior/Key Person Profile component.
Organizational DUNS
The applicant organization must include its DUNS number in its Organization Profile in the eRA Commons. This DUNS number must match the DUNS number provided at CCR registration with Grants.gov. For additional information, see Frequently Asked Questions Application Guide, Electronic Submission of Grant Applications.
SPECIAL INSTRUCTIONS
All
application instructions outlined in the SF 424 (R&R) Application Guide (http://grants.nih.gov/grants/funding/424/SF424_RR_Guide_General_Ver2.pdf) are to be followed, incorporating Just-in-Time
information concepts, with the following exceptions, which are specific
requirements for Director’s Pathfinder applications. Applications that do not conform to the specific
instructions detailed below will not be reviewed.
The following documents must be attached to
the application: Abstract, Public Health Relevancy Statement, Essay,
Biographical Sketch (PD/PI only), List of Current and Pending Research Support,
a description of the applicant’s most significant research accomplishment, a
Facilities Statement, and, if applicable, plans for Human and Vertebrate Animal
Subjects. All documents must be in PDF format and must comply with page limits
shown below. Note that the eRA system will not warn applicants that have
failed to include required attachments. Applicants should be extra diligent in
ensuring their applications are responsive to the requirements outlined below
and in the application guide.
1. SF424 (R&R) COVER COMPONENT:
Item Number 8. Type of Application: Must be New .
Item Number 12. Proposed Project: Enter start date: 09/30/2010; Enter end date: 9/29/2013.
Item Number 15. Estimated Project Funding: Cannot exceed $2,000,000.
2. R&R Other Project Information Component:
Item Number 7. Project Summary/Abstract: Attach abstract of 300 words or less describing the goals of the project. Text only no figures, animations, or Web links are allowed.
Item Number 8. Project Narrative: Attach Public Health Relevance Statement: In 2 3 sentences using plain language, describe how the proposed research will improve diversity within the biomedical research workforce.
Item Number 8. Bibliography & References Cited: Do not use. Reference citations are not required, but may be included in the essay and would be included in the 6-page limit.
Item Number 9. Facilities & Other Resources: Do not use. Include a brief statement of the facilities to be used for the conduct of the research in the List of Current and Pending Research Support document included with the PD/PI information on the R&R Senior/Key Person Profile form.
Item Number 10. Equipment: Do not use.
Item Number 11. Other Attachments: All applicants must attach the following document: Most Significant Research Accomplishment (see detailed instructions immediately below).
Most Significant Research Accomplishment: Attach a description of no more than one page of the applicant’s single most significant publication or research accomplishment. Applicants should submit one single accomplishment, not a summary of several accomplishments, multiple publications, or background narratives. Publications or other documents will not be accepted.
3. PHS 398 Research Plan:
Essay: In 6 pages maximum attached as item 3 (Research Strategy), describe the applicant’s innovative vision for addressing diversity within the biomedical research workforce, the importance of this problem on an institutional and a national level, and the applicant’s qualifications to engage in groundbreaking research related to workforce diversity. No detailed scientific plan should be provided since the research plan is expected to evolve during the tenure of the grant. The essay should include the following sections in the order given with the headings as shown below:
4. SF424 (R & R) SENIOR/KEY PERSON PROFILE COMPONENT:
Profile PD/PI Attach Biographical Sketch: Complete items only for Project Director/Principal Investigator. Do not submit biosketches for other senior/key personnel. Attach PD/PI’s biographical sketch, two pages maximum, following the sample format shown in the URL in Section 4.5.2 of the Application Guide, omitting Section C, Research Support.) No other biographical sketches are to be submitted.
Profile PD/PI Attach Current and Pending Support: Attach a list of Current and Pending Support from all sources, including current year direct costs and percent effort devoted to each project. Use the format shown in Section 3.1.1.8 of the Application Guide. A statement must be included that, if chosen to receive an award, the applicant will commit a major portion of their research effort, generally 30% or more to the project supported by the Director’s Pathfinder Award. In cases where the PD/PI cannot commit at least 30% effort, the PD/PI must justify the reduced effort and provide assurance that the project will not be compromised.
Profile Senior Key Person 1: Do not use. Submit information only for PD/PI. Information on collaborators or other key personnel is not required but may be included in the Essay.
5. Research & Related Budget:
The entire budget request should be entered in Budget Period 1.
6. PHS 398 Cover Letter (Optional):
Cover Letters should not be included unless related to an application which was corrected during the two day checking period after submission in grant.gov
(See full instructions for submitting the Cover Letter Component in Section 5.2 of the Application Guide. Note: Items 3 6 of the Guide do not apply to Director s Pathfinder applications.)
7. Letters of Reference:
Letters of reference are an important component of the Director’s Pathfinder application. Applicants must arrange to have three (and no more than three) letters of reference submitted on their behalf. Applications that are missing letters of reference may be considered non-responsive and may not be reviewed. Late letters will not be accepted. Applicants are responsible for monitoring the submission of their letters to ensure that three letters have been submitted prior to the submission deadline. Letters of Reference are submitted separate from the grant application directly through eRA Commons. Applicants are encouraged to check the status of their reference letter submissions in their Commons accounts.
Letters may be submitted beginning April 5, 2010, and must be submitted no later than 5:00 p.m. (EST) May 4, 2010.
To submit a letter of reference, the referee will need the following information:
Letters of reference are confidential. Applicants will not have access to the letters. E-mail confirmations will be sent to both the applicant and the referee. The confirmation sent to the applicant will include the referee’s name and the date and time the letter was submitted. The confirmation sent to the referee will include the referee and applicant’s names, a confirmation number, and the date and time the letter was submitted.
Note: Since e-mail can be unreliable, it is the applicant’s responsibility to check the status of his/her letters of reference periodically in the Commons.
Instructions for Referees:
Letters may be submitted to the Commons at (https://public.era.nih.gov/commons/public/reference/submitReferenceLetter.do?mode=new) beginning April 5, 2010 and must be submitted no later than 5:00 p.m. (EST), May 4, 2010. Late letters will not be accepted and applications with fewer than three letters may not be reviewed. Letters must be submitted electronically paper copies will not be accepted.
The applicant’s name should be placed at the top of the letter. Although signatures are not required, the letter must include a signature block with the referee’s full name, title, institution, and contact information.
In two pages or less, describe the applicant’s qualities that support the applicant’s claim to scientific innovativeness and creativity. When possible, give specific examples that illustrate these qualities. Address the likelihood that the applicant will conduct groundbreaking research related to scientific workforce diversity.
Note:
The letter submission page can be accessed without signing into the Commons,
and referees do not need to be registered in the Commons. Referees must
provide the applicant’s Commons User Name (User ID) and the other information
below:
REFEREE INFORMATION (the individual providing the letter of reference):
APPLICANT INFORMATION (applicants must send this information to their referees):
E-mail confirmations will be sent to both the applicant and the referee following submission of the letter. The email confirmation will include a Confirmation Number that will be required only when submitting a revised or changed/corrected letter. Please print the confirmation email for your records.
Please see the detailed instructions the Frequently Asked Questions at http://grants.nih.gov/recovery/faqs_directors_pathfinder.html. Send question to [email protected]
Appendix Materials
Appendices are not allowed and will not be accepted. Applications that contain attachments other than those specified may be rejected during the agency validation process.
No supplemental/update information will be accepted.
Resource Sharing Plan(s)
The following resource sharing plans will be
requested as just-in-time information if an award is being considered:
Section V. Application Review Information
1. Criteria
Only the
review criteria described below will be considered in the review process.
2. Review and Selection Process
The mission of the NIH is to support science in pursuit of knowledge about the biology and behavior of living systems and to apply that knowledge to extend healthy life and reduce the burdens of illness and disability. As part of this mission, applications submitted to the NIH for grants or cooperative agreements to support biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Applications that are complete and responsive to this FOA will be evaluated for scientific and technical merit by a an appropriate peer review group convened by Center for Scientific Review (CSR) on behalf of the Office of the Director, NIH, and in accordance with NIH peer review procedures (http://grants1.nih.gov/grants/peer), using the review criteria stated below. Those candidates who are identified as the most outstanding will be invited to NIH for interviews in July 2010. Interviews will be conducted by a panel of distinguished outside experts. In addition, the Advisory Committee to the Director (ACD), NIH, will conduct the final level of review. The Director, NIH, will make the final selection of awardees based on the outcome of the initial peer review, the recommendations of the ACD, and programmatic considerations. Final selection of awardees will be in September 2010.
Overall Impact. Reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following five scored review criteria, and additional review criteria (as applicable for the project proposed). For this Pathfinder Award mechanism, particular emphasis is placed on both the ability of the PD/PI to have a major impact in the field and the innovation of the approach or concept proposed, which must be substantially different from what the PD/PI or others have used before.
Scored Review Criteria. Reviewers will consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact.
Significance. Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? If successful, will this project offer significant new insights related to workforce diversity?
Investigator(s). Is the PD/PI well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? Is there evidence that the PD/PI understands the importance of scientific workforce diversity? Is there evidence that the PD/PI understands how legal issues may influence the proposed plan of research? Is there evidence that the PD/PI has been innovative, creative, and productive given her/his career stage? Does the PD/PI have the necessary stature to ensure institutional support for the planned research? Is there evidence that the PI will commit sufficient effort to the proposed project?
Innovation. Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Does the proposed research reflect ideas substantially different from those already pursued by the PD/PI or others?
Approach. Are the overall strategy, methodology, and proposed analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?
If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?
Environment. Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Is there evidence of institutional support for the planned research?
2.A. Additional Review Criteria
As applicable for the project proposed, reviewers will consider the following additional items in the determination of scientific and technical merit, but will not give separate scores for these items.
Protections for Human Subjects. For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials.
Inclusion of Women, Minorities, and Children. When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children.
Vertebrate Animals. The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia. . For additional information, see http://grants.nih.gov/grants/olaw/VASchecklist.pdf.
Resubmission Applications. Resubmission applications are not permitted in response to this FOA.
Renewal Applications. Renewal applications are not permitted in response to this FOA.
Revision Applications. Revision applications are not permitted in response to this FOA.
Biohazards. Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Applications from Foreign Organizations. Not permitted in response to this FOA.
Select Agent Research. Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource
Sharing Plans. Will be expected if an award is
considered likely, or an explanation of why sharing is not possible.
All applicants will receive summary statements with brief reviewer
comments. Additionally, applicants selected for finalist interviews will
receive overall impact/priority scores. Criterion scores will be provided
to either finalists or non-finalists.
Budget and Period Support. Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Appeals will not be permitted. See NOT-OD-09-054, Recovery Act of 2009: NIH Review Criteria, Scoring System, and Suspension of Appeals Process.
Selection Process The following will be considered in making funding decisions:
3.
Anticipated Announcement and Award Dates
Applicants will be notified of their status - whether or not they have been
selected for interviews - in June, 2010. The earliest award date
will be August 31, 2010.
Section VI. Award Administration Information
1. Award Notices
After the peer review of the application
is completed, the PD/PI will be able to access his or her Summary Statement
(written critique) via the NIH eRA Commons.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant. For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General. In addition, as part of just-in-time information for those Recovery Act awards, for any modular budget application, a detailed budget will be required prior to award.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official.
The terms of the NoA will reference the requirements of the Recovery Act.
In addition to the standard NIH terms of award, all awards will be subject to the HHS Standard Terms and Conditions for Recovery Act awards. The full text of these terms approved for NIH awards can be found in the following document: Standard Terms and Conditions for AARA Awards.
Selection of an application for award is not an
authorization to begin performance. Any costs incurred before receipt of the
NoA are at the recipient's risk. These costs may be reimbursed only to the
extent considered allowable pre-award costs. See Section
IV.5., Funding Restrictions.
2.
Administrative and National Policy Requirements
All NIH grant and cooperative agreement
awards include the NIH Grants Policy Statement as part of the NoA. For
these terms of award, see the NIH Grants Policy Statement Part
II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and
Conditions for Specific Types of Grants, Grantees, and Activities.
The following terms and conditions will be incorporated into the NoA and will be provided to the PD/PI and the appropriate institutional official at the time of award.
1. This award provides funding for an application submitted in response to RFA-OD-10-013. This grant should be administered in accordance with the guidelines described in this specific announcement. These guidelines are in addition to the standard Terms and Conditions referenced in Section III of this Notice of Grant Award.
2a. When issuing statements, press releases, and other documents describing projects or programs funded as a Directors Pathfinder Award, please use the following acknowledgement: "This work was funded by the National Institutes of Health through the NIH Director's Pathfinder Award to Promote Diversity in the Scientific Workforce, grant number DP4-OD-xxxxxx.
2b. As indicated in the FOA, awardees are generally expected to commit 30% or more (specifying agreed amount) of their research effort to the project supported by the Director’s Pathfinder Award.
2c. Awardees are expected to attend an annual symposium in the Bethesda, MD, area.
3.
Reporting
Awardees will be required to submit the Non-Competing
Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants
Policy Statement.
In addition, grantees must comply with the requirements set forth in the Recovery Act, including, but not limited to, the reporting requirements described in Section 1512 of the Act, as well as applicable OMB guidance regarding the use of Recovery Act funds. As noted above, grantees must also comply with the HHS Standard Terms and Conditions for Recovery Act awards. The full text of these terms approved for NIH awards can be found in the following document: Standard Terms and Conditions for ARRA Awards.
Recovery Act-related reporting requirements will be incorporated as a special term of award.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated. Until such time as HHS has migrated to the SF 425 FFR, award recipients will utilize the SF 269 FSR.
This funding announcement is subject to restrictions on oral conversations during the period of time commencing with the submission of a formal application[1] by an individual or entity and ending with the award of the competitive funds. Federal officials may not participate in oral communications initiated by any person or entity concerning a pending application for a Recovery Act competitive grant or other competitive form of Federal financial assistance, whether or not the initiating party is a federally registered lobbyist[1]. This restriction applies unless:
(i) the communication is purely logistical;
(ii) the communication is made at a widely attended gathering;
(iii) the communication is to or from a Federal agency official and another Federal Government employee;
(iv) the communication is to or from a Federal agency official and an elected chief executive of a state, local or tribal government, or to or from a Federal agency official and the Presiding Officer or Majority Leader in each chamber of a state legislature; or
(v) the communication is initiated by the Federal agency official.
For additional information see http://www.whitehouse.gov/omb/assets/memoranda_fy2009/m09-24.pdf
We encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research (program), peer review, and financial or grants management issues:
1. Scientific/Research Contact(s):
Pre and Post-award
Clifton Poodry, Ph.D.
Division of Minority
Opportunities in Research
National Institute of
General Medical Sciences
45 Center Drive, Room 2AS.37 MSC 6200
Bethesda, MD 20892-6200
Telephone: (301)
594-3900
FAX: (301) 480-2753
Email: [email protected]
Email: [email protected] (e-mail is the strongly preferred method for inquiries)
2. Peer Review Contact(s):
John Firrell Ph.D.
Scientific Review Officer
Surgical Sciences, Biomedical Imaging and Bioengineering IRG
Center for Scientific Review
National Institutes of Health
6701 Rockledge Dr, Room 5118
Bethesda, MD 20892
Phone: (301) 435-2598
Fax (301) 480-2241
[email protected]
Email: [email protected] (e-mail is the strongly preferred method for inquiries)
3. Financial/Grants Management Contact(s):
Mr. E.C. Melvin
Grants
Management Officer
Cell
Biology and Biophysics
National
Institute of General Medical Sciences
45 Center
Drive,
Rm 2As.32E, MSC 6200
Bethesda, MD 20892-6200
Telephone:
301-594-3912
FAX:
301-480-2554
Email: [email protected]
Section VIII. Other Information
Required Federal Citations
The American Recovery And Reinvestment Act of 2009 (Pub. L. No. 111-5): http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=111_cong_bills&docid=f:h1enr.pdf
Standard Terms and Conditions for Recovery Act Awards: The full text of these terms approved for NIH awards can be found in the following document: http://grants.nih.gov/grants/policy/NIH_HHS_ARRA_Award_Terms.pdf
Use of Animals in
Research:
Recipients of PHS support for activities involving live, vertebrate animals
must comply with PHS Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act
of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects
Protection:
Federal regulations (45 CFR 46) require that applications and proposals
involving human subjects must be evaluated with reference to the risks to the
subjects, the adequacy of protection against these risks, the potential
benefits of the research to the subjects and others, and the importance of the
knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety
Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials,
including physiologic toxicity and dose-finding studies (Phase I); efficacy
studies (Phase II); efficacy, effectiveness and comparative trials (Phase III).
Monitoring should be commensurate with risk. The establishment of data and
safety monitoring boards (DSMBs) is required for multi-site clinical trials
involving interventions that entail potential risks to the participants ( NIH
Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, http://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct
costs in any single year are expected to include a plan for data sharing or
state why this is not possible (http://grants.nih.gov/grants/policy/data_sharing). Investigators should seek guidance from their
institutions, on issues related to institutional policies and local
institutional review board (IRB) rules, as well as local, State and Federal
laws and regulations, including the Privacy Rule.
Policy for Genome-Wide
Association Studies (GWAS):
NIH is interested in advancing genome-wide association studies (GWAS) to
identify common genetic factors that influence health and disease through a
centralized GWAS data repository. For the purposes of this policy, a
genome-wide association study is defined as any study of genetic variation
across the entire human genome that is designed to identify genetic
associations with observable traits (such as blood pressure or weight), or the
presence or absence of a disease or condition. All applications, regardless of
the amount requested, proposing a genome-wide association study are expected to
provide a plan for submission of GWAS data to the NIH-designated GWAS data
repository, or provide an appropriate explanation why submission to the
repository is not possible. Data repository management (submission and access)
is governed by the Policy for Sharing of Data Obtained in NIH Supported or
Conducted Genome-Wide Association Studies, NIH Guide NOT-OD-07-088. For additional information, see http://grants.nih.gov/grants/gwas/.
Sharing of Model
Organisms:
NIH is committed to support efforts that encourage sharing of important
research resources including the sharing of model organisms for biomedical
research (see http://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights
of grantees and contractors to elect and retain title to subject inventions
developed with Federal funding pursuant to the Bayh-Dole Act (see the NIH Grants Policy Statement. Beginning October 1, 2004, all investigators
submitting an NIH application or contract proposal are expected to include in
the application/proposal a description of a specific plan for sharing and
distributing unique model organism research resources generated using NIH
funding or state why such sharing is restricted or not possible. This will
permit other researchers to benefit from the resources developed with public
funding. The inclusion of a model organism sharing plan is not subject to a
cost threshold in any year and is expected to be included in all applications
where the development of model organisms is anticipated.
Access to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to
provide access to research data through the Freedom of Information Act (FOIA)
under some circumstances. Data that are: (1) first produced in a project that
is supported in whole or in part with Federal funds; and (2) cited publicly and
officially by a Federal agency in support of an action that has the force and
effect of law (i.e., a regulation) may be accessed through FOIA. It is
important for applicants to understand the basic scope of this amendment. NIH
has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected
under this funding opportunity in a public archive, which can provide
protections for the data and manage the distribution for an indefinite period
of time. If so, the application should include a description of the archiving
plan in the study design and include information about this in the budget
justification section of the application. In addition, applicants should think
about how to structure informed consent statements and other human subjects
procedures given the potential for wider use of data collected under this
award.
Inclusion of Women And
Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their
sub-populations must be included in all NIH-supported clinical research
projects unless a clear and compelling justification is provided indicating
that inclusion is inappropriate with respect to the health of the subjects or
the purpose of the research. This policy results from the NIH Revitalization
Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing
clinical research should read the "NIH Guidelines for Inclusion of Women and
Minorities as Subjects in Clinical Research (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is
available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an
NIH definition of clinical research; updated racial and ethnic categories in
compliance with the new OMB standards; clarification of language governing
NIH-defined Phase III clinical trials consistent with the SF424 (R&R)
application; and updated roles and responsibilities of NIH staff and the
extramural community. The policy continues to require for all NIH-defined Phase
III clinical trials that: a) all applications or proposals and/or protocols
must provide a description of plans to conduct analyses, as appropriate, to
address differences by sex/gender and/or racial/ethnic groups, including
subgroups if applicable; and b) investigators must report annual accrual and
progress in conducting analyses, as appropriate, by sex/gender and/or
racial/ethnic group differences.
Inclusion of Children as
Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all clinical research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them. All
investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as
participants in research involving human subjects (http://grants.nih.gov/grants/funding/children/children.htm).
Required Education on
the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants
for all investigators submitting NIH applications for research involving human
subjects and individuals designated as key personnel. The policy is available
at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem
Cells (hESC):
Criteria
for Federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-116.html.
Only research using hESC lines that are registered in the NIH Human Embryonic
Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov/). It is the responsibility
of the applicant to provide in the project description and elsewhere in the
application as appropriate, the official NIH identifier(s) for the hESC line(s)
to be used in the proposed research.
NIH Public Access Policy
Requirement:
In accordance with the NIH Public Access Policy, investigators funded by the
NIH must submit or have submitted for them to the National Library of
Medicine’s PubMed Central (see http://www.pubmedcentral.nih.gov/), an electronic version of their final,
peer-reviewed manuscripts upon acceptance for publication, to be made publicly
available no later than 12 months after the official date of publication. The
NIH Public Access Policy is available at (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-033.html). For more information, see the Public
Access webpage at http://publicaccess.nih.gov/.
Standards for Privacy of
Individually Identifiable Health Information:
The Department of Health and Human Services (HHS) issued final modification to
the "Standards for Privacy of Individually Identifiable Health
Information", the "Privacy Rule", on August 14, 2002. The
Privacy Rule is a federal regulation under the Health Insurance Portability and
Accountability Act (HIPAA) of 1996 that governs the protection of individually
identifiable health information, and is administered and enforced by the HHS
Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule,
including a complete Regulation Text and a set of decision tools on "Am I
a covered entity?" Information on the impact of the HIPAA Privacy Rule on
NIH processes involving the review, funding, and progress monitoring of grants,
cooperative agreements, and research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant
Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within
specified page limitations. For publications listed in the appendix and/or
Progress report, Internet addresses (URLs) or PubMed Central (PMC) submission
identification numbers must be used for publicly accessible on-line journal
articles. Publicly accessible on-line journal articles or PMC
articles/manuscripts accepted for publication that are directly relevant to the
project may be included only as URLs or PMC submission
identification numbers accompanying the full reference in either the
Bibliography & References Cited section, the Progress Report Publication
List section, or the Biographical Sketch section of the NIH grant application.
A URL or PMC submission identification number citation may be repeated in each
of these sections as appropriate. There is no limit to the number of URLs or
PMC submission identification numbers that can be cited.
Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2010," a PHS-led
national activity for setting priority areas. This FOA is related to one or
more of the priority areas. Potential applicants may obtain a copy of
"Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and
Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental
review requirements of Executive Order 12372. Awards are made under the
authorization of Sections 301 and 405 of the Public Health Service Act as
amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and
45 CFR Parts 74 and 92. All awards are subject to the terms and conditions,
cost principles, and other considerations described in the NIH Grants Policy Statement.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood
development services are provided to children. This is consistent with the PHS
mission to protect and advance the physical and mental health of the American
people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified
health professionals who have made a commitment to pursue a research career
involving clinical, pediatric, contraception, infertility, and health
disparities related areas. The LRP is an important component of NIH's efforts
to recruit and retain the next generation of researchers by providing the means
for developing a research career unfettered by the burden of student loan debt.
Note that an NIH grant is not required for eligibility and concurrent career
award and LRP applications are encouraged. The periods of career award and LRP
award may overlap providing the LRP recipient with the required commitment of
time and effort, as LRP awardees must commit at least 50% of their time (at
least 20 hours per week based on a 40 hour week) for two years to the research.
For further information, please see: http://www.lrp.nih.gov/.
[1] Formal application includes the preliminary application and letter of intent phases of the program.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||